CHN1 is a Novel Prognostic Marker for Diffuse Large B-Cell Lymphoma

PURPOSE: Diffuse large B-cell lymphoma (DLBCL) is the most common B-cell malignancy. Thirty to forty percent of DLBCL patients still experience relapse or develop refractory disease even with standard immunochemotherapy, leading to a poor prognosis. Currently, although several gene-based classificat...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Pharmgenomics Pers Med
Asıl Yazarlar: Sun, Jie, Zhu, Xiaoquan, Zhao, Yanyang, Zhou, Qi, Qi, Ruomei, Liu, Hui
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove 2021
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8021264/
https://ncbi.nlm.nih.gov/pubmed/33833551
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PGPM.S301718
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller